Anti-VEGF combined with fufang xueshuangtong versus anti-VEGF monotherapy for wet age-related macular degeneration: A meta-analysis

Tingke Xie , Yanyan Lan , Chengming Chen , Jing Han
{"title":"Anti-VEGF combined with fufang xueshuangtong versus anti-VEGF monotherapy for wet age-related macular degeneration: A meta-analysis","authors":"Tingke Xie ,&nbsp;Yanyan Lan ,&nbsp;Chengming Chen ,&nbsp;Jing Han","doi":"10.1016/j.prmcm.2025.100598","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the effectiveness and safety of combining anti-VEGF and fufang xueshuangtong in the treatment of wet age-related macular degeneration (wet AMD).</div></div><div><h3>Methods</h3><div>A systematic review of studies focusing on the efficacy and safety of the combined anti-VEGF and Fufang Xueshuantong therapy versus anti-VEGF monotherapy for wet AMD was conducted. This meta-analysis was performed based on a protocol registered in PROSPERO (CRD42024593135). The outcomes were reported as weighted mean differences (MDs) with corresponding 95 % confidence intervals (CI) or risk ratio (RR) with 95 % CI.</div></div><div><h3>Results</h3><div>A total of 9 studies, involving 731 participants, were included. The MD for best-corrected visual acuity (BCVA) improvement, central macular thickness (CMT), and size of choroidal neovascularization (CNV) between the combination therapy and monotherapy groups were 7.37 (95 % CI [5.35 to 9.39]), −35.57 (95 % CI [−47.02 to −24.12]), and −1.81 (95 % CI [−2.56 to −1.07]), respectively. Additionally, the combination therapy group showed greater improvement in serum and ocular hemodynamics and had a lesser impact on intraocular pressure, and there was no significant difference in the incidence of adverse reactions between the two regimens.</div></div><div><h3>Conclusions</h3><div>The combination of anti-VEGF therapy with Fufang Xueshuantong provides superior efficacy compared to anti-VEGF monotherapy in the treatment of wet AMD and is associated with an improved safety profile. However, further trials are needed to enhance the robustness and reliability of these findings.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"15 ","pages":"Article 100598"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Research - Modern Chinese Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667142525000272","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

To evaluate the effectiveness and safety of combining anti-VEGF and fufang xueshuangtong in the treatment of wet age-related macular degeneration (wet AMD).

Methods

A systematic review of studies focusing on the efficacy and safety of the combined anti-VEGF and Fufang Xueshuantong therapy versus anti-VEGF monotherapy for wet AMD was conducted. This meta-analysis was performed based on a protocol registered in PROSPERO (CRD42024593135). The outcomes were reported as weighted mean differences (MDs) with corresponding 95 % confidence intervals (CI) or risk ratio (RR) with 95 % CI.

Results

A total of 9 studies, involving 731 participants, were included. The MD for best-corrected visual acuity (BCVA) improvement, central macular thickness (CMT), and size of choroidal neovascularization (CNV) between the combination therapy and monotherapy groups were 7.37 (95 % CI [5.35 to 9.39]), −35.57 (95 % CI [−47.02 to −24.12]), and −1.81 (95 % CI [−2.56 to −1.07]), respectively. Additionally, the combination therapy group showed greater improvement in serum and ocular hemodynamics and had a lesser impact on intraocular pressure, and there was no significant difference in the incidence of adverse reactions between the two regimens.

Conclusions

The combination of anti-VEGF therapy with Fufang Xueshuantong provides superior efficacy compared to anti-VEGF monotherapy in the treatment of wet AMD and is associated with an improved safety profile. However, further trials are needed to enhance the robustness and reliability of these findings.
抗vegf联合复方血肿通与抗vegf单药治疗湿性年龄相关性黄斑变性的meta分析
目的评价抗vegf联合复方血爽通治疗湿性年龄相关性黄斑变性(wet age-related macular degeneration, wet AMD)的有效性和安全性。方法系统评价抗vegf联合复方血栓通治疗湿性AMD与抗vegf单药治疗的疗效和安全性。本荟萃分析基于在PROSPERO (CRD42024593135)注册的方案进行。结果以加权平均差异(MDs)报告,相应的95%置信区间(CI)或95% CI的风险比(RR)。结果共纳入9项研究,731名受试者。联合治疗组和单一治疗组最佳矫正视力(BCVA)改善、黄斑中央厚度(CMT)和脉络膜新生血管大小(CNV)的MD分别为7.37 (95% CI[5.35 ~ 9.39])、- 35.57 (95% CI[- 47.02 ~ - 24.12])和- 1.81 (95% CI[- 2.56 ~ - 1.07])。此外,联合治疗组血清和眼血流动力学改善更大,对眼压的影响更小,两种方案的不良反应发生率无显著差异。结论复方血栓通联合抗vegf治疗湿性AMD的疗效优于单药治疗,且安全性更高。然而,需要进一步的试验来提高这些发现的稳健性和可靠性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信